| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.01 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.088 | 0.01 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | -0.072 | 0.01 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.27 | 0.01 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.079 | 0.02 |